CORT CORCEPT THERAPEUTICS INC Insider Trading

CFO Atabak Mokari sells 40,000 shares for $3.5M via scheduled 10b5-1 plan; 16,130 shares remain.

Atabak Mokari, Chief Financial Officer of Corcept Therapeutics, executed 4 separate sales totaling 40,000 shares for $3,508,277.12 on 2026-07-15 at a blended average price of $87.71, reducing his non-derivative holdings from 56,130 to 16,130 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-12, meaning it was scheduled and not discretionary. His prior 5 trades at this same ticker show 30-day gains ranging from +8.6% to +26.4%, suggesting previous sales have occurred ahead of price appreciation; however, the 90-day outcome window is not yet measurable for any of those trades. The company's fundamentals remain challenged: net income stands at $-31,761,000.00 against $164,903,000.00 in quarterly revenue, and the P/E ratio of 205.73 reflects the current stock valuation. The insider retains derivative holdings of 4,167 and 175,833 stock options across two vehicles, preserving meaningful upside participation.

CDO William Guyer sells 20,000 shares for $1.9M at avg $93.13 via scheduled 10b5-1 plan; retains 130,000 stock options

William Guyer, Chief Development Officer, executed 2 separate sales totaling 20,000 shares for $1,862,529.64 on 2026-07-07 under a pre-arranged 10b5-1 trading plan adopted on 2024-11-27. His post-transaction non-derivative holdings stand at 3,985 shares, while he retains 130,000 shares in stock option holdings (Table II). This scheduled disposition occurred as the stock has moved +26.7% over 30 days and +120.0% over 90 days from the 52-week low of $28.66, now trading at $92.94, near the 52-week high of $94.77. His prior sales at CORT have shown mixed outcomes: recent sales on 2026-06-02 and 2026-05-05 yielded 30-day returns of +27.8% and +44.5%, respectively, though earlier 2025-12-02 and 2025-11-05 sales showed 90-day returns of -55.5%, -55.1%, and -46.6%. The company remains unprofitable with $-31.8M net income on $164.9M quarterly revenue, though annual revenue growth stands at +12.8% year-over-year.

Sean Maduck sells 25,000 CORT shares across 3 transactions for $2.2M via scheduled 10b5-1 plan

Sean Maduck executed 3 separate sales totaling 25,000 shares for $2,208,736.56 on 2026-07-01 under a pre-arranged 10b5-1 trading plan adopted 2025-12-08, reducing his non-derivative holdings to 9,755 shares (a -71.9% reduction from 34,755 shares). While the sale represents a material decrease in his direct shareholding, Maduck retains 116,986 shares via stock option holdings (Table II derivative securities). His prior trades at CORT show consistent gains in the 30-day window (26.2%, 25.1%, 32.0%, 33.6% on four recent sales) before one prior December 2025 sale underperformed (-56.2% at 30d, -55.1% at 90d), though these outcomes are not predictive of current-period results. The transaction is scheduled per the 10b5-1 plan, not discretionary timing. With CORT trading 1.3% below its 52-week high and showing a +26.2% 30-day return, the sale does not occur during a depressed valuation window.

Director Mahoney sells 20,000 CORT shares at $84.53; stock now $81.75 vs $91.00 high; prior 2 sells at CORT both well-timed at 90d.

David L Mahoney sold 20,000 shares (43.3% of his holdings) at $84.53 on 2026-06-17, reducing his stake from 46,147 to 26,147 shares for total proceeds of $1,690,506.00. The stock has since fallen to $81.75, currently -10.2% from its 52-week high of $91.00, placing this sale within a broader positive 30-day (+48.3%) and 90-day (+139.9%) momentum context. Notably, both of his prior sales at CORT (on 2025-05-16) were well-timed at the 90-day mark, with negative post-sale returns of -3.6% and -2.9% respectively, suggesting a pattern of sales preceding declines at this ticker. The company reports a net loss of $31.8M against revenue of $164.9M (latest quarter), with a steep P/E of 185.80 and market cap of $8.8B, indicating significant valuation relative to profitability. This sale, combined with his consistent 90-day timing accuracy on prior CORT sales, warrants tracking of the stock's subsequent performance to confirm whether the pattern holds.

CFO Atabak Mokari sold 40,000 shares ($3.2M) at $80.02–$82.45 on 2026-06-15 via scheduled 10b5-1 plan; retains 16,130 non-derivative shares and 20,000 option holdings.

CFO Atabak Mokari executed four separate sales totaling 40,000 shares for $3,245,900.04 on 2026-06-15 under a pre-arranged 10b5-1 trading plan adopted 2025-12-12, reducing his non-derivative holdings by 71.3% from 56,130 shares to 16,130 shares. The sales occurred at prices ranging from $80.02 to $82.45 (blended average $81.15), while the stock now trades at $81.75 and has climbed 139.9% over the past 90 days and 48.3% over the past 30 days from a 52-week range of $28.66–$91.00. Corcept is trading at a P/E of 185.80 with a -$31.8M net loss in the latest quarter despite $164.9M in revenue and 12.8% annual growth. Because this sale is scheduled under a 10b5-1 plan rather than discretionary, it reflects a pre-established trading arrangement rather than a timing decision by the insider; the executive retains 20,000 shares via stock options alongside his 16,130 non-derivative shares.

CDO William Guyer sells 20,000 CORT shares at $70.60 under pre-arranged 10b5-1 plan; retains 150,000 stock options.

William Guyer, Chief Development Officer of Corcept Therapeutics, sold 20,000 shares at $70.60 on 2026-06-02 as part of a scheduled 10b5-1 trading plan adopted on 2024-11-27. The trade reduced his direct shareholding from 23,985 to 3,985 shares while leaving 150,000 stock options intact. The stock has appreciated 40.8% over the prior 30 days and 113.4% over 90 days, and currently trades at $72.65—near its 52-week range of $28.66–$91.00 and only 20.2% below the recent high. Across his same-ticker history at CORT, Guyer's five prior sales show a volatile pattern: gains in the 30 days following two May 2026 and November 2025 sales, but losses between -55.1% and -57.0% over 90 days after both December 2025 sales. The company is unprofitable (net income $-31.8M against revenue of $164.9M) with a elevated P/E of 165.11. Because this sale is pre-arranged and scheduled rather than discretionary, the filing provides limited signal about Guyer's current conviction; investors should note the structured execution and monitor whether the company's profitability trajectory aligns with its valuation.

Sean Maduck sells 25,000 shares (71.9% of holdings) at $70.21 blended price under 10b5-1 plan

Sean Maduck executed 2 separate sales totaling 25,000 shares for $1,755,183.48 on 2026-06-01 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-08, reducing non-derivative holdings from 34,755 to 9,755 shares (-71.9% vs pre-transaction holdings). The current stock price of $72.65 sits -20.2% from the 52-week high of $91.00, yet Maduck retains 141,986 shares in stock options (derivative securities), indicating his economic interest in CORT remains substantial despite the scheduled share disposition. His prior 5 sales at CORT have produced mixed 30-day and 90-day outcomes (ranging from -56.2% to +13.1% in the 30-day window), while his cross-ticker track record shows an average 90-day return of -13.4% after his 20 prior sells across all tickers.

CFO Atabak Mokari sold 40,000 shares of CORT at $70.00 under pre-arranged 10b5-1 plan; retains 16,130 non-derivative shares plus stock options.

Atabak Mokari, CFO of Corcept Therapeutics, executed a scheduled sale of 40,000 shares at $70.00 on 2026-06-01 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-12, reducing his non-derivative holdings to 16,130 shares. The company is currently trading at $72.65, up 40.8% over 30 days and 113.4% over 90 days, yet remains unprofitable with net income of $-31,761,000.00 against quarterly revenue of $164,903,000.00. The sale represents a scheduled, discretionary-free transaction rather than a market-timing decision, but the confluence of significant stock appreciation, continued operating losses, and substantial reduction in the CFO's direct equity stake merits investor attention regarding capital allocation priorities during a period of rapid price gains.

CEO Joseph K Belanoff sold 12,837 shares of CORT at $69.74 under scheduled 10b5-1 plan adopted 2024-11-26

Joseph K Belanoff, Chief Executive Officer, sold 12,837 shares (12.8K shares) of CORCEPT THERAPEUTICS INC (CORT) at $69.74 on 2026-06-01 for a total value of $895,252.38 ($895.3K), reducing his holdings from 2,578,326 shares (2.58M shares) to 2,565,489 shares (2.57M shares), a reduction of -0.5% vs pre-transaction holdings. This sale was part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-26, meaning it was scheduled and not discretionary. At the same ticker, Belanoff's prior five trades show mixed performance: recent sells on 2026-05-01 and 2026-03-25 were followed by positive 30-day returns of +38.7% and negative returns of -8.0% respectively, while earlier sales in late 2025 predominantly resulted in negative 90-day returns (-55.2%, -45.2%, and -46.4%). The company reports a net loss of $-31.8M on revenue of $164.9M, with a P/E ratio of 161.82, reflecting a highly valued unprofitable company; the CEO's substantial remaining stake of 2.57M shares demonstrates continued material alignment with shareholder interests despite the liquidation.

Sean Maduck sells 75,000 shares (89.3% of holdings) for $4.9M under 10b5-1 plan at $65.59 avg; stock now +49.2% in 30 days

Sean Maduck executed 2 separate sales totaling 75,000 shares for $4,918,943.74 on 2026-05-27 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-08, reducing his non-derivative holdings from 83,977 shares to 8,977 shares. The sales occurred at blended average price of $65.59; CORT stock has since moved to $69.49 (current price), representing a +49.2% 30-day change from the transaction date. This transaction is scheduled rather than discretionary per the 10b5-1 plan flag. Maduck retains 166,986 shares through stock option holdings (Table II), meaning his overall economic position extends beyond the non-derivative shares sold. His prior open-market history across all tickers shows an average 90-day return of -13.4% following 20 prior sells, while his same-ticker history at CORT over 5 prior trades shows mixed results: the most recent prior sale on 2025-12-01 experienced a -56.2% 30-day decline, though earlier sales at this ticker showed smaller 30-day reversals.